keyword
MENU ▼
Read by QxMD icon Read
search

rheumatoid arthritis remission

keyword
https://www.readbyqxmd.com/read/29338762/predictors-of-remission-with-etanercept-methotrexate-induction-therapy-and-loss-of-remission-with-etanercept-maintenance-reduction-or-withdrawal-in-moderately-active-rheumatoid-arthritis-results-of-the-preserve-trial
#1
Josef S Smolen, Annette Szumski, Andrew S Koenig, Thomas V Jones, Lisa Marshall
BACKGROUND: The aim was to analyze characteristics that predict remission induction and subsequent loss of remission in patients with moderately active rheumatoid arthritis (RA) who received full-dose combination etanercept plus methotrexate induction therapy followed by reduced-dose etanercept or etanercept withdrawal. METHODS: Patients with Disease Activity Score based on 28-joint count (DAS28) >3.2 and ≤5.1 received open-label etanercept 50 mg once weekly (QW) plus methotrexate for 36 weeks...
January 16, 2018: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29336711/circulating-serum-interleukin-6-serum-chitinase-3-like-protein-1-and-plasma-vascular-endothelial-growth-factor-are-not-predictive-for-remission-and-radiographic-progression-in-patients-with-early-rheumatoid-arthritis-post-hoc-explorative-and-validation-studies
#2
C H Brahe, C Dehlendorff, M Østergaard, J S Johansen, L M Ørnbjerg, K Hørslev-Petersen, K Stengaard-Pedersen, P Junker, T Ellingsen, H Lindegaard, I Hansen, T Lottenburger, S Jacobsen, A G Jurik, M L Hetland
OBJECTIVE: To investigate serum interleukin-6 (IL-6), serum chitinase-3-like protein-1 (YKL-40), and plasma vascular endothelial growth factor (VEGF) as measures of disease activity and predictors of clinical remission and radiographic progression in two early rheumatoid arthritis (RA) randomized controlled trials (RCTs). METHOD: Treatment-naïve patients with early RA (< 6 months' duration) and active disease, participating in two investigator-initiated RCTs, were treated according to a predefined treat-to-target algorithm aiming at inflammatory control, using methotrexate (MTX) + cyclosporine versus MTX + placebo (CIMESTRA study, n = 150, 5 year follow-up) or MTX + adalimumab versus MTX + placebo (OPERA study, n = 180, 2 year follow-up)...
January 16, 2018: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/29335344/can-ultrasound-be-used-to-predict-loss-of-remission-in-patients-with-ra-in-a-real-life-setting-a-multicenter-cohort-study
#3
Pascal Zufferey, Almut Scherer, Michael J Nissen, Adrian Ciurea, Giorgio Tamborrini, Laure Brulhart, Sandra Blumhardt, Martin Toniolo, Burkhard Möller, Hans-Ruedi Ziswiler
OBJECTIVE: Several studies have suggested that patients with rheumatoid arthritis (RA) presenting with ultrasound (US) synovitis despite clinical remission have more subsequent flares than those who show both clinical and sonographic remission. The objective of our study was to investigate whether these results could be translated to a real-life setting. METHODS: We compared the time from the first US performed in clinical remission to loss of remission (defined by a DAS28 > 2...
January 15, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29334721/efficacy-and-safety-of-tocilizumab-in-korean-patients-with-active-rheumatoid-arthritis
#4
Han Joo Baek, Mie Jin Lim, Won Park, Sung Hwan Park, Seung-Cheol Shim, Dae-Hyun Yoo, Hyun Ah Kim, Soo Kon Lee, Yun Jong Lee, Young Eun Park, Hoon-Suk Cha, Yeong-Wook Song
Background/Aims: To investigate the efficacy and safety of tocilizumab (TCZ) humanized anti-interleukin-6 receptor monoclonal antibody, in Korean patients with active rheumatoid arthritis (RA) refractory to conventional disease modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX). Methods: The main study was a 24-week, randomized, double-blind, controlled trial that was followed by a 48-week, open-labeled, extension phase. TCZ (8 mg/kg) or placebo was intravenously administered every 4 weeks...
January 17, 2018: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29323343/targeting-lymphatic-function-as-a-novel-therapeutic-intervention-for-rheumatoid-arthritis
#5
REVIEW
Echoe M Bouta, Richard D Bell, Homaira Rahimi, Lianping Xing, Ronald W Wood, Clifton O Bingham, Christopher T Ritchlin, Edward M Schwarz
Although clinical outcomes for patients with rheumatoid arthritis (RA) have greatly improved with the use of biologic and conventional DMARDs, approximately 40% of patients do not achieve primary clinical outcomes in randomized trials, and only a small proportion achieve lasting remission. Over the past decade, studies in murine models point to the critical role of the lymphatic system in the pathogenesis and therapy of inflammatory-erosive arthritis, presumably by the removal of catabolic factors, cytokines and inflammatory cells from the inflamed synovium...
January 11, 2018: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/29322372/examination-of-patient-reported-outcomes-in-association-with-tnf-inhibitor-treatment-response-results-from-a-us-observational-cohort-study
#6
Cynthia J Larmore, Natalie N Boytsov, Carol L Gaich, Xiang Zhang, Andre B Araujo, Sabrina Rebello, Bob A Salim, George W Reed, Leslie R Harrold
INTRODUCTION: Implementation of a treat-to-target strategy is challenging when the patient and physician prioritize different goals. This study aimed to "translate" improvements in Clinical Disease Activity Index (CDAI) to concepts that resonate with patients (such as pain, fatigue, morning stiffness) by examining the association between changes in disease activity and patient-reported outcomes (PROs) in a national cohort of patients with rheumatoid arthritis (RA) initiating their first biologic treatment...
January 10, 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29315512/driving-chronicity-in-rheumatoid-arthritis-perpetuating-role-of-myeloid-cells
#7
REVIEW
Stefano Alivernini, Barbara Tolusso, Gianfranco Ferraccioli, Elisa Gremese, Mariola Kurowska-Stolarska, Iain B McInnes
Acute inflammation is a complex and tightly regulated homeostatic process that includes leukocyte migration from the vasculature into tissues to eliminate the pathogen/injury, followed by a pro-resolving response promoting tissue repair. However, if inflammation is uncontrolled as in chronic diseases such as Rheumatoid Arthritis (RA) it leads to tissue damage and disability. Synovial tissue inflammation in RA patients is maintained by sustained activation of multiple inflammatory positive-feedback regulatory pathways in a variety of cells including myeloid cells...
January 8, 2018: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/29314738/long-term-efficacy-and-safety-of-add-on-tacrolimus-for-persistent-active-rheumatoid-arthritis-despite-treatment-with-methotrexate-and-tumor-necrosis-factor-inhibitors
#8
Taio Naniwa, Shiho Iwagaitsu, Mikiko Kajiura
AIM: To assess the long-term efficacy and safety of adding tacrolimus for patients with active rheumatoid arthritis (RA) despite anti-tumor necrosis factor (TNF) therapy with methotrexate. METHODS: Consecutive patients who were treated with adding tacrolimus onto anti-TNF therapy with methotrexate for active RA despite anti-TNF therapy with methotrexate, were retrospectively analyzed in terms of treatment response, achieving remission, subsequent treatment tapering and adverse events...
January 4, 2018: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29303709/cost-effectiveness-of-early-treatment-of-acpa-positive-rheumatoid-arthritis-patients-with-abatacept
#9
Aljoscha S Neubauer, Christof Minartz, Kirsten H Herrmann, Christoph G O Baerwald
OBJECTIVES: Studies have reported that the presence of elevated anti-citrullinated protein antibodies (ACPA)/RF levels, together with joint erosions, is associated with higher disease burden in terms of disability and mortality in rheumatoid arthritis (RA). Abatacept has been shown to be effective in this patient population with favourable comparative data against adalimumab. However, few studies have investigated the cost-effectiveness of abatacept in this population to similar treatments such as TNFs...
December 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29297205/cyclophosphamide-for-connective-tissue-disease-associated-interstitial-lung-disease
#10
REVIEW
Hayley Barnes, Anne E Holland, Glen P Westall, Nicole Sl Goh, Ian N Glaspole
BACKGROUND: Approximately one-third of individuals with interstitial lung disease (ILD) have associated connective tissue disease (CTD). The connective tissue disorders most commonly associated with ILD include scleroderma/systemic sclerosis (SSc), rheumatoid arthritis, polymyositis/dermatomyositis, and Sjögren's syndrome. Although many people with CTD-ILD do not develop progressive lung disease, a significant proportion do progress, leading to reduced physical function, decreased quality of life, and death...
January 3, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29294598/rapid-onset-of-efficacy-predicts-response-to-therapy-with-certolizumab-plus-methotrexate-in-patients-with-active-rheumatoid-arthritis
#11
Young Mo Kang, Young-Eun Park, Won Park, Jung-Yoon Choe, Chul-Soo Cho, Seung-Cheol Shim, Sang Cheol Bae, Chang-Hee Suh, Hoon-Suk Cha, Eun Mi Koh, Yeong-Wook Song, Bin Yoo, Shin-Seok Lee, Min-Chan Park, Sang-Heon Lee, Catherine Arendt, Willem Koetse, Soo-Kon Lee
Background/Aims: The objective of this study was to determine the efficacy and safety of add-on therapy with certolizumab pegol (CZP) in active rheumatoid arthritis (RA) patients of a single ethnicity. Methods: In this 24-week, phase 3, randomized, double-blind, placebo-controlled trial, eligible patients (n = 127) were randomized 2:1 to subcutaneous CZP + methotrexate (MTX; 400 mg at week 0, 2, and 4 followed by 200 mg every 2 weeks) or placebo + MTX. Results: At week 24, the American College of Rheumatology criteria for 20% (ACR20) response rate was significantly greater with CZP + MTX than with placebo (66...
January 5, 2018: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29282619/dickkopf-1-protein-circulating-levels-as-a-possible-biomarker-of-functional-disability-and-chronic-damage-in-patients-with-rheumatoid-arthritis
#12
Ana M Santos, Eugenia-Lucía Saldarriaga, Rodrigo Giraldo-Bustos, Jesus Giovanny Ballesteros-Muñoz, Juan C Rueda, Francy-Milena Cuervo, José-Ignacio Angarita, Andrés Y Vásquez, Sofía Arias-Correal, Camilo A González, Pedro Santos-Moreno, John Londono
Rheumatoid arthritis (RA) is an inflammatory disease characterized by joint destruction, deformity, lower functionality, and decrease in life expectancy. Wingless signaling pathway (Wnt) has been recently involved in bone homeostasis. Studies suggest that overexpression of the pathway inhibitors, like the Dickkopf 1 protein (DKK1), has been implicated in bone destruction. The objective of this study is to compare circulating levels of DKK1 in different groups of patients with disease activity (remission, low, moderate, high activity,) and functionality status...
December 27, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/29280011/high-burden-of-adverse-events-is-associated-with-reduced-remission-rates-in-early-rheumatoid-arthritis
#13
Laura Kuusalo, Kari Puolakka, Hannu Kautiainen, Anna Karjalainen, Timo Malmi, Leena Paimela, Marjatta Leirisalo-Repo, Vappu Rantalaiho
Adverse events (AEs) are common during disease-modifying antirheumatic drug (DMARD) treatment, but their influence on treatment results is unclear. We studied AEs in relation to disease activity in early rheumatoid arthritis (RA). Ninety-nine patients started intensive treatment with three conventional synthetic DMARDs (csDMARDs) and oral prednisolone, and were randomized to a 6-month induction treatment with infliximab or placebo. All AEs during the first 12 months of treatment were recorded. We scored each AE based on severity (scale 1-4) and defined the burden of AEs as the sum of these scores...
December 26, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/29278006/relationship-between-disease-activity-and-patient-reported-outcomes-in-rheumatoid-arthritis-post-hoc-analyses-of-overall-and-japanese-results-from-two-phase-3-clinical-trials
#14
Naoki Ishiguro, Maxime Dougados, Zhihong Cai, Baojin Zhu, Masato Ishida, Masayo Sato, Carol Gaich, Amanda Quebe, Ivaylo Stoykov, Yoshiya Tanaka
OBJECTIVE: To examine patient-reported outcomes (PROs) in patients with different rheumatoid arthritis (RA) disease activity levels and identify residual symptoms. METHODS: Post hoc analyses of overall and Japanese data from two randomized controlled trials including RA patients with previous inadequate responses to methotrexate (NCT01710358) or no/minimal previous disease-modifying antirheumatic drug treatment (NCT01711359) (sponsor: Eli Lilly and Company). Week 24 assessments were disease activity (Simplified Disease Activity Index, Disease Activity Score/Disease Activity Score 28 joints-erythrocyte sedimentation rate) and PROs (pain visual analog scale [VAS], morning joint stiffness [MJS], Health Assessment Questionnaire-Disability Index, Functional Assessment of Chronic Illness Therapy-Fatigue, and Medical Outcomes Study Short Form 36 Health Survey Physical and Mental Component Scores)...
December 26, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/29251034/residual-symptoms-and-disease-burden-among-patients-with-rheumatoid-arthritis-in-remission-or-low-disease-activity-a-systematic-literature-review
#15
Masato Ishida, Yuki Kuroiwa, Emiko Yoshida, Masayo Sato, Dominika Krupa, Nathaniel Henry, Kei Ikeda, Yuko Kaneko
OBJECTIVES: To identify, describe and summarize evidence on residual symptoms and disease burdens in rheumatoid arthritis (RA) patients qualified as being in remission or low disease activity (LDA). METHODS: A systematic literature review (SLR) was conducted according to Cochrane collaboration guidelines. The population of interest was adult patients with RA in remission or LDA. The reported outcomes of interest were any symptoms or burdens. RESULTS: 51 publications were identified through an e-database search...
December 18, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/29251032/safety-and-effectiveness-of-subcutaneous-tocilizumab-in-patients-with-rheumatoid-arthritis-in-a-real-world-clinical-setting
#16
Tatsuya Atsumi, Keishi Fujio, Kunihiro Yamaoka, Minako Tomobe, Kazuyuki Kuroyanagi, Hideto Kameda, Yoshiyuki Moriguchi
OBJECTIVES: To evaluate the safety and effectiveness of subcutaneous tocilizumab (TCZ-SC) in a real-world clinical setting in Japan. METHODS: This single arm, 26-week prospective observational study enrolled patients with RA who were either TCZ naïve or switched from TCZ-IV to TCZ-SC (TCZ-IV-SC group) (UMIN Clinical Trials Registry UMIN000011102). All patients received TCZ-SC 162 mg every 2 weeks and data were collected until week 26 or discontinuation. RESULTS: Overall 784 (78...
December 18, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/29248952/a-comprehensive-care-program-achieves-high-remission-rates-in-rheumatoid-arthritis-in-a-middle-income-setting-experience-of-a-center-of-excellence-in-colombia
#17
Pedro Santos-Moreno, Nelson J Alvis-Zakzuk, Laura Villarreal-Peralta, Maria Carrasquilla-Sotomayor, Angel Paternina-Caicedo, Nelson Alvis-Guzmán
Management of rheumatoid arthritis (RA) in many Latin-American countries is impaired by fragmentation and scarce healthcare provision, resulting in obstacles to access, diagnosis, and treatment, and consequently in poor health outcomes. The aim of this study is to propose a comprehensive care program as a model to provide healthcare to RA patients receiving synthetic DMARDs in a Colombian setting by describing the model and its results. Health outcomes were prospectively collected in all patients entering the program...
December 16, 2017: Rheumatology International
https://www.readbyqxmd.com/read/29247149/two-year-efficacy-and-safety-of-subcutaneous-tocilizumab-in-combination-with-disease-modifying-antirheumatic-drugs-including-escalation-to-weekly-dosing-in-rheumatoid-arthritis
#18
Alan Kivitz, Ewa Olech, Michael A Borofsky, Beatriz Zazueta, Federico Navarro-Sarabia, Sebastião C Radominski, Joan T Merrill, César Pacheco-Tena, Jinglan Pei, Clare Nasmyth-Miller, Janet E Pope
OBJECTIVE: To evaluate the longterm efficacy and safety of subcutaneous tocilizumab (TCZ-SC) every 2 weeks (q2w) over 2 years in patients with rheumatoid arthritis who have an inadequate response to disease-modifying antirheumatic drugs (DMARD). METHODS: Patients (n = 656) were randomized 2:1 to TCZ-SC 162 mg q2w or placebo-SC q2w plus DMARD. After a 24-week double-blind period, patients (n = 457) were rerandomized to open-label TCZ-SC q2w by means of prefilled syringe or autoinjector...
December 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29246530/controversies-in-rheumatoid-arthritis-glucocorticoid-therapy
#19
Adeline Ruyssen-Witrand, Arnaud Constantin
Despite therapeutic innovations in the past 20 years, glucocorticoids (GC) are still widely used for the symptomatic treatment of rheumatoid arthritis (RA). Studies have demonstrated the clinical and structural efficacy of moderate doses (i.e. 30-60 mg/d) GC in addition to disease modifying anti-rheumatic drug (DMARD) initiation in early RA. A combination of a low dose of GC (i.e. 7.5-10 mg/d) and DMARDs increases remission rates and decreases the risk of medium-term structural progression in early RA. Intravenous and intramuscular administration of GC associated with DMARD initiation or intra-articular GC injections in symptomatic joints in tight control strategies increase remission rates in early RA...
December 12, 2017: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/29246162/use-of-a-baseline-risk-score-to-identify-the-risk-of-serious-infectious-events-in-patients-with-rheumatoid-arthritis-during-certolizumab-pegol-treatment
#20
Jeffrey R Curtis, Kevin Winthrop, Cathy O'Brien, Matladi N Ndlovu, Marc de Longueville, Boulos Haraoui
BACKGROUND: The risk of serious infectious events (SIEs) is increased in patients with rheumatoid arthritis (RA). The aim of this study was to develop an age-adjusted comorbidity index (AACI) to predict, using baseline characteristics, the SIE risk in patients with RA treated with certolizumab pegol (CZP). METHODS: Data of CZP-treated patients with RA were pooled from the RAPID1/RAPID2 randomized controlled trials (RCT CZP) and their open-label extensions (All CZP)...
December 15, 2017: Arthritis Research & Therapy
keyword
keyword
52663
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"